Trials / Completed
CompletedNCT02062684
BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Anthera Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy with persistent proteinuria of between 1-6 g/day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blisibimod | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2017-03-01
- Completion
- 2017-06-30
- First posted
- 2014-02-14
- Last updated
- 2017-09-18
Locations
23 sites across 10 countries: Czechia, Germany, Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT02062684. Inclusion in this directory is not an endorsement.